We are holding another community chat on Wednesday 17th June at 7pm. If anyone would like to join please let me know your email address & I’ll send you the link 😊
Big news today: Vijoice (Alpelisib) has been approved for use by the EMA. This medication addresses an unmet medical need for patients with severe or life-threatening PIK3CA-related overgrowth spectrum (PROS) disorders
https://t.co/HEMPgL6TiF
Very interesting presentation by Iksha Kumar on a patient with AVM and a PIK3CA mutation showing a good response to Alpelisib. Others shared they also have patients with CLOVES syndrome and spinal AVMs with PIK3CA mutations, also showing good responses to Alpelisib. #ISSVA
We are very grateful to our supporters Karen, Helen, Eva & Jack who are undertaking a 18 mile walk for GoPI3Ks. If you’d like to donate & support them please see link here:
https://t.co/QoY3hMEjC8
🚨 Funding Opportunity 🚨
Early career researchers in CLA and Isolated LMs: apply for the Alfie Milne Young Investigator Award.
📅 LOI due May 29, 2026 (11:59 PM ET)
🔗 https://t.co/omDvo33la6
Please share with colleagues.
#lymphaticmalformations#complexlymphaticmalformations
I came across this paper from 2023, a really comprehensive read with many interesting insights including: Evaluations Following Initial Diagnosis, Treatment & Recommended Surveillance for Individuals with PIK3CA-Related Overgrowth Spectrum: https://t.co/CyySA6KWCu